Abstracts tagged "Behcet’s syndrome"

Abstract Number: 2747 • 2014 ACR/ARHP Annual Meeting
Identification of Potential Serum Biomarkers for Behcet Disease By High Resolution Quantitative Proteomic Analysis
Yongjing CHENG Jr.¹, Xiaolin Sun², Yuling Chen Jr.³, Cibo Huang⁴, Haiteng Deng³ and Zhan-Guo Li⁵, ¹Rheumatology and Immunology Department, Beijing Hospital, Ministry of Health, Beijing, China, ²People's hospital,Peking University, Beijing, China, ³Tsing hua University, Beijing, China, ⁴Beijing hospital, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Behcet’s disease (BD) is a chronic, multisystemic vasculitis, pathogenesis of BD remains enigmatic. Diagnosis of BD is sometimes difficult, and until now, no specific…
Abstract Number: 2748 • 2014 ACR/ARHP Annual Meeting
Microparticles May Play a Role in Causing Thrombosis in Behçet’s Syndrome and Act As a Biomarker for Risk Management
Emon Khan¹, Nicola Ambrose¹, Michael A. Laffan² and Dorian O. Haskard³, ¹Department of Vascular Sciences, National Heart and Lung Institute, Imperial College, London, United Kingdom, ²Department of Haemostasis and Thrombosis, Imperial College, London, United Kingdom, ³Rheumatology, Imperial College, London, United Kingdom
Background/Purpose Thrombosis occurs in 20% of patients with Behçet’s Syndrome (BS) and leads to significant morbidity. There is no robust association between thrombosis in BS…
Abstract Number: 2749 • 2014 ACR/ARHP Annual Meeting
The Clinical Course of Acute Deep Vein Thrombosis of the Legs in Behçet’s Syndrome
Melike Melikoglu¹, Yesim Ozguler², Serdal Ugurlu³, Firat Cetinkaya⁴, Koray Tascilar², Emire Seyahi³, Vedat Hamuryudan³ and Hasan Yazici¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁴Radiology, Colormed Radiology Center, Istanbul, Turkey
Background/Purpose To determine the prospective clinical course of lower extremity deep vein thrombosis (LEDVT) in patients with Behçet’s syndrome (BS). Methods Consecutive BS patients with…
Abstract Number: 2750 • 2014 ACR/ARHP Annual Meeting
Effects of Anticoagulant Treatment on the Incidence of New Vascular Events in Patients with Behcet’s Disease with Vascular Involvement
Fatma Alibaz-Oner¹, Aslı Karadeniz², Sema Yilmaz³, Ayse Balkarli⁴, Gezmis Kimyon⁵, Ayten Yazici⁶, Muhammed Cinar⁷, Sedat Yilmaz⁷, Fatih Yildiz⁸, Sule Yasar Bilge⁹, Emre Bilgin¹⁰, Belkıs Nihan Şeniz¹¹, Ahmet Omma¹², Gozde Yildirim Cetin¹³, Yonca Cagatay¹⁴, Mehmet Sayarlioglu¹⁵, Yavuz Pehlivan¹⁶, Umut Kalyoncu¹⁷, Omer Karadag¹⁰, Timucin Kasifoglu⁹, Eren Erken⁸, Salih Pay⁷, Ayse Cefle⁶, Bunyamin Kisacik¹⁸, Ahmet Mesut Onat¹⁹, Veli Cobankara²⁰ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, ³Department of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, ⁴Department of Rheumatology, Pamukkale University School of Medicine, Denizli, Turkey, ⁵Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Department of Rheumatology, Kocaeli University, Kocaeli, Turkey, ⁷Rheumatology, Gulhane Military Medical Academy, Ankara, Turkey, ⁸Rheumatology, Cukurova University, School of Medicine, Adana, Turkey, ⁹Rheumatology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey, ¹⁰Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹¹Rheumatology, Uludağ University, School of Medicine, Bursa, Turkey, ¹²Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹³Rheumatology, Kahramanmaras University School of Medicine, Kahramanmaras, Turkey, ¹⁴Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ¹⁵Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey, ¹⁶Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ¹⁷PsAID taskforce, EULAR, Zurich, Switzerland, ¹⁸Rheumatology, Gaziantep University, School of Medicine, Gaziantep, Turkey, ¹⁹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ²⁰Rheumatology, Pamukkale University, School of Medicine, Denizli, Turkey
Background/Purpose: Vascular involvement (VI) is one of the major causes of mortality and morbidity in Behcet's Disease (BD). There are no controlled studies for the…
Abstract Number: 2751 • 2014 ACR/ARHP Annual Meeting
18F-FDG PET/CT in Vascular Disease Due to Behçet’s Syndrome
Emire Seyahi¹, Metin Hallac², Betul Vatankulu³, Serdal Ugurlu¹, Melike Melikoglu⁴, Sebahattin Yurdakul¹ and Hasan Yazici⁴, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Department of Nuclear Medicine, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Turkey, ³Department of Nuclear Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT is considered as a useful tool in assessing active vascular inflammation in large vessel vasculitis. Lower extremity vein…
Abstract Number: 2752 • 2014 ACR/ARHP Annual Meeting
Budd-Chiari Syndrome Due to Behçet’s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome
Emire Seyahi¹, Erkan Caglar², Serdal Ugurlu¹, Fatih Kantarci³, Vedat Hamuryudan¹, Abdullah Sonsuz⁴, Melike Melikoglu⁵, Sebahattin Yurdakul¹ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Gastroenterology, Department of Internal Medicine, Bakirkoy Research and Training Hospital, Istanbul, Turkey, ³Department of Radiology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, ⁴Department of Gastroenterology, Cerrahpasa Medical Faculty of Istanbul Universit, Cerrahpasa Medical Faculty of Istanbul University, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose Behçet’s syndrome (BS) is a well recognized cause of Budd–Chiari syndrome (BCS), however, information about its clinical characteristics and outcome is limited. We had…
Abstract Number: 2853 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Paz Rodríguez-Cundín², Emma Beltrán³, Juan Sánchez Bursón Sr.⁴, Marina Mesquida⁵, Alfredo Adan⁵, M. Victoria Hernández⁶, Marisa Hernandez Grafella⁷, Elia Valls Pascual⁸, Lucía Martinez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero-Coma¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹², Jose Luis García Serrano¹³, Norberto Ortego-Centeno¹⁴, Jose M Herreras¹⁵, Alejandro Fonollosa¹⁶, Angel M. Garcia-Aparicio¹⁷, Olga Maiz Alonso¹⁸, Ana Blanco¹⁹, Ignacio Torre Salaberri²⁰, Cruz Fernández- Espartero²¹, Vega Jovani²², Diana Peiteado²³, Esperanza Pato²⁴, Juan Cruz²⁵, Carlos Férnandez Cid²⁶, Elena Aurrecoechea²⁷, Miriam García-Arias²⁸, Miguel Angel Caracuel-Ruiz²⁹, Carlos Alberto Montilla Morales³⁰, Antonio Atanes-Sandoval³¹, Félix Francisco³², Santos Insua³³, Senen González-Suárez³⁴, Maria Amalia Sanchez Andrade³⁵, Fernando Gamero³⁶, Luis Francisco Linares Ferrando³⁷, Fredeswinda Romero³⁸, A. Javier García-González³⁹, Raquel Almodóvar González⁴⁰, Enrique Minguez⁴¹, Carmen Carrasco Cubero⁴², Alejandro Olive⁴³, Julio Vázquez⁴⁴, Oscar Ruiz Moreno⁴⁵, Fernando Jiménez-Zorzo⁴⁵, Javier Manero⁴⁵, Santiago MuÑoz Fernandez⁴⁶, Javier Rueda-Gotor¹, Trinitario Pina¹, Montserrat Santos-Gómez¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁴Rheumatology. Hospital de Valme., Sevilla, Spain, ⁵Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁷Ophthalmology. Hospital General universitario de Valencia, Valencia, Spain, ⁸Rheumatology. Hospital Peset, Valencia, Spain, ⁹Ophthalmology. Hospital Peset, Valencia, Spain, ¹⁰H. Vall d'Hebron, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹³Ophthalmology. Hospital San Cecilio, Granada, Spain, ¹⁴Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁵Ophthalmology. Hospital Universitario, IOBA, Valladolid, Spain, ¹⁶Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ¹⁷Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ¹⁸Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹⁹Ophthalmology. Hospital Donosti, San Sebastián, Spain, ²⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ²¹Rheumatology, Hospital Universitario de Móstoles. Madrid. Spain, Madrid, Spain, ²²Rheumatology. Hospital General de Alicante, Alicante, Spain, ²³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²⁴Rheumatology. Hospital Clínico San Carlos, Madrid, Spain, ²⁵Rheumatology. Hospital de Pontevedra, Pontevedra, Spain, ²⁶Ophthalmology. Hospital de Pontevedra, Pontevedra, Spain, ²⁷Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁸Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁹Plaza Cruz Roja, 1, H. Reina Sofia, Cordoba, Spain, ³⁰Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³¹Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, ³²Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ³³Rheumatology. Hospital Universitario Santiago de Compostela, A Coruña, Spain, ³⁴Rheumatology. Hospital Cabueñes, Gijón, Spain, ³⁵Hosp. Lucus Augusti, Lugo, Spain, ³⁶Rheumatology. Hospital San Pedro Alcantara, Cáceres, Spain, ³⁷Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ³⁸Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ³⁹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁴⁰Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁴¹Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴²Rheumatology, Hospital de Merida, Mérida, Spain, ⁴³Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, ⁴⁴Rheumatology. Hospital de Ferrol, A Coruña, Spain, ⁴⁵Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ⁴⁶Sección de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
Background/Purpose: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year…
Abstract Number: 2753 • 2014 ACR/ARHP Annual Meeting
Reduced Heart Rate Variability in Patients with Behcet’s Disease
Joung-Wook Lee¹, Seung-Geun Lee², Eun-Kyoung Park² and Geun-Tae Kim³, ¹Divsion of Rheumatology, Department of Internal Medicine, Busan St. Marys center, Busan, South Korea, ²Divsion of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea
Background/Purpose The autonomic nervous system, including the sympathetic and parasympathetic nervous systems, has an important role in the triggering of ventricular arrhythmias and sudden cardiac…
Abstract Number: 2854 • 2014 ACR/ARHP Annual Meeting
Effect of Apremilast on Quality of Life and Physical Function in Patients with Behçet’s Syndrome
Gulen Hatemi¹, Melike Melikoglu¹, Recep Tunc², Cengiz Korkmaz³, Banu Turgut Ozturk⁴, Cem Mat⁵, Peter A. Merkel⁶, Kenneth Calamia⁷, Lilia Pineda⁸, Ziqi Liu⁸, Randall M. Stevens⁸, Hasan Yazici¹ and Yusuf Yazici⁹, ¹Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, ³EskiÅŸehir Osmangazi University, EskiÅŸehir, Turkey, ⁴Selçuk University, Konya, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Dermatology, Istanbul, Turkey, ⁶Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁷Administration, Mayo Clinic Health System in Waycross, Waycross, GA, ⁸Celgene Corporation, Warren, NJ, ⁹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: The oral ulcers in Behçet’s syndrome (BS) can be painful, causing difficulty in eating and speaking, and can impair the quality of life. Apremilast…
Abstract Number: 2732 • 2014 ACR/ARHP Annual Meeting
Massive Ex Vivo Expansion of Functionally Stable Behcet’s Patient-Derived Regulatory T Cell Clones
Johannes Nowatzky¹, Olivier Manches¹, Yusuf Yazici² and Juan Lafaille¹, ¹New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Adoptive transfer of regulatory T cells (Treg) is a promising strategy for the treatment of human autoimmune diseases. Most currently tested approaches focus on…
Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
Peter C. Grayson¹, Yusuf Yazici², Elaine Novakovich³, Elizabeth Joyal⁴, Raphaela T. Goldbach-Mansky⁴ and Cailin H. Sibley^3,5, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴NIAMS, National Institutes of Health Clinical Center, Bethesda, MD, ⁵Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…
Abstract Number: 2208 • 2014 ACR/ARHP Annual Meeting
Ovarian Reserve Alterations in Premenopausal Women with Rheumatoid Arthritis, Behcet’s Disease and Spondyloarthritis – Impact on Anti-Muellerian Hormone Levels
Joerg C. Henes¹, Julia Froeschlin², Andre Taran³, Theodoros Xenitidis⁴ and Melanie Henes⁵, ¹Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ²University Tuebingen, Tuebingen, Germany, ³University Hospital for Women Tuebingen, Tuebingen, Germany, ⁴Internal Medincine II, devision for Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁵University Hospital for Women, Tuebingen, Germany
Background/Purpose: Recent publications showed a negative influence of systemic lupus erythematosus and antiphospholipid antibody syndrome on female ovarian reserve (OR). Other authors did not find…
Abstract Number: 2757 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients
Hélène Vallet¹, Sophie Rivière², Alban Deroux³, Guillaume Moulis⁴, Olga Addimanda⁵, Carlo Salvarani⁶, Marc Lambert⁷, Philip Bielfeld⁸, Pascal Sève⁹, Jean Sibilia¹⁰, Jean Baptiste Fraison¹¹, Yoland Schoindre¹², Isabelle Marie¹³, Laurent Perard¹⁴, Thomas Papo¹⁵, Damien Sène¹⁶, Gaelle Leroux¹⁷, Valerie Royant¹⁸, Antoinette Perlat¹⁹, Xavier Mariette²⁰, Olivier Lidove²¹, Olivier Fain²², Claire De Moreuil²³, Gilles Blaison²⁴, Phuc LE Hoang²⁵, Eric Hachulla²⁶, Bertrand Wechsler²⁷, Barham Bodaghi²⁸, Patrice Cacoub²⁹ and David Saadoun³⁰, ¹Internal medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Internal Medicine, Lapeyronie, Montpellier, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Internal Medicine department, Toulouse, Toulouse, France, ⁵S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ⁶Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁷CHRU Lille, Lille, France, ⁸CHU de Dijon, Dijon, France, ⁹Internal medicine, CHU Lyon, Lyon, France, ¹⁰Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹¹Hôpital Jean Verdier, Bondy, France, ¹²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, ¹³CHU de Rouen, Rouen, France, ¹⁴Hospices civils de Lyon, Lyon, France, ¹⁵Hôpital Bichat, Paris, France, ¹⁶Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁷Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁸Chartres, Chartres, France, ¹⁹Internal medicine, CHU de Rennes, Rennes, France, ²⁰rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ²¹Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, ²²Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ²³CHU, Brest, France, ²⁴Internal medicine, CHR, Colmar, France, ²⁵Ophtalmology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpétrière, Paris, France, ²⁶Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, ²⁷Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²⁸Ophtalmology, Hôpital de la Pitié Salpêtrière, Paris, France, ²⁹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ³⁰DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose Behçet’s disease (BD) is a systemic large vessel vasculitis with recurrent genital and oral ulceration, uveitis, cardiovascular, joints, neurological or gut symptoms. Treatment of…
Abstract Number: 1339 • 2014 ACR/ARHP Annual Meeting
Is Psychological Status Related to Symptom Experience in Behçet’s Syndrome?
Robert Moots¹ and Sophie Campbell², ¹Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ²Behcets Centre, Aintree University Hospital, Liverpool, United Kingdom
Background/Purpose Little is known about the impact of Behçet’s Syndrome (BS) within the UK. The recent establishment of National Centres of Excellence now allows a…
Abstract Number: 2629 • 2013 ACR/ARHP Annual Meeting
Is Complete Remission a Realistic Target With Current Therapeutic Options in Behçet’s Disease ?
Fatma Alibaz-Oner¹, Gonca Mumcu², Zeynep Kubilay³, Gülsen Ozen⁴, Gülce Celik³, Aslı Karadeniz³, Meryem Can⁵, Sibel Yılmaz Oner¹, Nevsun Inanc⁶, Pamir Atagunduz⁷, Tülin Ergun⁸ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ³Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, ⁴Rheumatology, Marmara University School of Medicine., Istanbul, Turkey, ⁵Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Marmara University School of Medicine, Istanbul, Turkey, ⁷Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁸Dermatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: The clinical course of Behcet’s disease (BD) as a multi-systemic disorder with a remitting-relapsing nature is unsufficiently explored. As complete remission should be aimed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].